CF PharmTech jumps most on record on new hypertension drug application

CF PharmTech

16/03/2026 02:36

** Shares of China-based inhalation technologies and drugs developer CF PharmTech Inc 2652.HK soar 37.6% to HK$31.64; on course for the biggest one-day pct gain since debut on October 8

** Stock hits the highest since March 10

** Company said China's National Medical Products Administration had accepted investigational new drug (IND) application for its inhalation powder candidate ICF001 to treat pulmonary hypertension and related pulmonary diseases

** ICF001 possesses broad potential to expand into larger patient populations, such as those with pulmonary fibrosis associated with interstitial lung disease, in the future - Co

** YTD, stock down 12.9%, while Hang Seng Biotech Index .HSBIO up 0.3%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))